Ysebaert, Loïc <br/><br/>
Main clinical studies of Bruton’s tyrosine kinase inhibitors (BTKis) 

 -  2024.<br/>							 
<br/><br/> 86 
<br/><br/> Quality of life evaluation is crucial in therapeutic trials in hematology, but is not yet recognized as the only true patient-centered primary endpoint. For chronic lymphocytic leukemia patients, how can we move beyond focusing solely on progression-free survival to truly consider overall survival with good quality of life?